Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

PTC Therapeutics: Clinical Trials & FDA Approval Profile

PTC Therapeutics (Global / Institutional) sponsors 22 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (1 recruiting now), 10 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)31.8%
Median Closed Enrollment vs National (145 pts)68 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for PTC Therapeutics
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)22
Active Pipeline (Recruiting Now)5 (1)
Completed vs Stopped Early10 / 7 (31.8%)
Median Closed Actual Enrollment68 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With PTC Therapeutics
Hospital Research SiteLocationShared Protocols
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CA6
Children's Hospital of PhiladelphiaPhiladelphia, PA6
Stanford Health Care and Stanford Cancer InstituteStanford, CA4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by PTC Therapeutics
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05099640A Study of PTC923 in Participants With PhenylketonuriaPhase IIICOMPLETED
NCT05218655A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial DiseasePhase IIICOMPLETED
NCT05269355A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)Phase II/IIITERMINATED
NCT05349721Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALSPhase IITERMINATED
NCT03783923A Study of Deflazacort (Emflaza®) in Participants With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)Phase IIITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the PTC Therapeutics Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI